Latest press releases

Excelerate Energy, Inc.

Excelerate Energy Reports Strong Third Quarter 2026 Results

ALLEGIANT TRAVEL COMPANY

THIRD QUARTER 2026 FINANCIAL RESULTS*

Unisys Announces 3Q26 Results

Unisys Continues Strong New Business Signings and Raises Full-Year Revenue Guidance Revenue of $471.5 million, up 2.5% year over year (YoY), up 0.6%…

Blue Owl Capital Corporation Announces September 30, 2026 Financial Results

Blue Owl Capital Corporation (NYSE: OBDC) ("OBDC" or the "Company") today announced financial results for its third quarter ended September 30, 2026.…

Figma Announces Third Quarter 2026 Financial Results

Q3 revenue grew 43% year-over-year to $391.4 million, $16.4 million above the high-end of prior guidance.

Edwards Lifesciences Corp

FOR IMMEDIATE RELEASE

LeMaitre Q3 2026 Financial Results

ISLAND PACIFIC OPENS 22ND SUPERMARKET IN NORTHEAST LOS ANGELES

New Eagle Rock Boulevard location celebrates Filipino heritage, affordable groceries, and community connections. LOS ANGELES, Nov. 4, 2026 — Island…

Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update

ENCORE CAPITAL GROUP INC

Encore Capital Group Announces Third Quarter 2026 Financial Results

TRUEBLUE REPORTS THIRD QUARTER 2026 RESULTS

Light & Wonder, Inc.

Reports Third Quarter 2026 Results

Citius Oncology’s Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma

Presented at Premier Global CLTG Congress in Europe

Warrior Reports Third Quarter 2026 Results

Generates $166.0 million of operating cash flows leading to recently announced $2.00 per-share special dividend

Rapid7 Announces Third Quarter 2026 Financial Results

•Annualized recurring revenue (“ARR”) of $820 million

Construction Partners, Inc. Completes Georgia Acquisition

Transaction Expands Company's Operations Along Growing Interstate 85 Corridor DOTHAN, Ala., Nov. 4, 2026 — Construction Partners, Inc. (NASDAQ: ROAD)…

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)

Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in…

THUNDER MOUNTAIN GOLD INC

Thunder Mountain Gold Announces Key Leadership AdditionStrengthening Exploration Team

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over…